Pyrophosphate imaging agent shortage reported, could last weeks

The American Society of Nuclear Cardiology (ASNC) is alerting its provider members of a pyrophosphate shortage, which could potentially last for weeks. 

The ASNC has received reports of imaging agent 99mTechnetium-pyrophosphate (PYP) being in low supply, citing statements it received from two manufacturers, Curium and Sun Radiopharma, who blame the shortage on supply chain disruptions.

According to the ASNC, Curium said it is working to find an alternative supplier to resume normal production as soon as possible. In its own statement, Sun Radiopharma provided a “best estimate” of January 2024 for PYP production to resume as normal.

The company also lists shortages in other radiopharmaceutical products, with estimates for when supplies will be available. The full statement from Sun Radiopharma can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.